… target in the era of immunotherapies. We offer a perspective on TLR-based therapeutics
that sheds light on their usefulness and on combination therapies. We also highlight various …

… or therapeutic target (265). Initial studies monitored MDSCs in cancer patients, analyzed total
MDSCs population (G-and M-MDSC together). The diversity of cell surface markers used to …

… -M and other novel immunotherapy methods, immunotherapy has entered a new era. At
present, evidence indicates that the combination of multiple immunotherapy methods may be …

… moved immunotherapy into a new era, and they represent paradigm-shifting therapeutic …
design and development of cancer therapies that target immune checkpoints. This article …

… source of intracellular therapeutic targets. Recently, we … useful targets for mAb-based or
vaccination immunotherapies… future uses of these immunotherapies against a large pool of …

… Currently, many epigenetic therapeutics targeting DNA, including methyltransferase inhibitors
and histone deacetylase inhibitors, have been widely used in clinical trials, and some of …

… of personalized immunotherapies that target neoantigens … on cancer vaccine therapies that
target similar neoantigens … attention as the new era of cancer immunotherapy. Meanwhile, …

… in the field of cancer immunotherapy over the last decade. Whilst … Focus was initially placed
on targeting cancers considered … with other therapies (immunotherapy, targeted therapy and …

… The CTLA-4 was the first checkpoint receptor to be clinically targeted. In an era lacking
effective therapies in the treatment of melanoma, ipilimumab was firstly approved by FDA in 2010 …

… A deeper understanding of the PD-1 blockade unresponsive mechanism from various
multidisciplinary aspects will still be necessary to identify new therapeutic targets to combine with …